{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T05:21:19Z","timestamp":1740892879685,"version":"3.38.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.clinthera.2010.09.013","type":"journal-article","created":{"date-parts":[[2010,12,29]],"date-time":"2010-12-29T09:15:21Z","timestamp":1293614121000},"page":"1842-1853","source":"Crossref","is-referenced-by-count":7,"title":["Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in thailand"],"prefix":"10.1016","volume":"32","author":[{"given":"Jutima","family":"Boonleang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weerachai","family":"Pipatrattanaseree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanpa","family":"Tanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werawath","family":"Mahatthanatrakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"first-page":"2499","year":"2009","series-title":"Risperidone. AHFS Drug Information 2009","key":"10.1016\/j.clinthera.2010.09.013_bib1"},{"key":"10.1016\/j.clinthera.2010.09.013_bib3","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00004714-199302000-00004","article-title":"A Canadian multicenter placebo-controlled study of fixed dose of risperidone and haloperidol in the treatment of chronic schizophrenic patients [published correction appears in J Clin Psychopharmacol. 1993;13:149]","volume":"13","author":"Chouinard","year":"1993","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2010.09.013_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry."},{"key":"10.1016\/j.clinthera.2010.09.013_bib5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s002130050322","article-title":"Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function","volume":"132","author":"Trevitt","year":"1997","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.09.013_bib6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.pnpbp.2003.10.006","article-title":"Adverse effects of risperidone and haloperidol treatment in schizophrenia","volume":"28","author":"Yen","year":"2004","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.clinthera.2010.09.013_bib7","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.clinthera.2010.09.013_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","article-title":"Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial","volume":"90","author":"Kane","year":"2007","journal-title":"Schizophr Res."},{"key":"10.1016\/j.clinthera.2010.09.013_bib9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.09.013_bib10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","article-title":"Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia","volume":"48","author":"Grant","year":"1994","journal-title":"Drugs."},{"key":"10.1016\/j.clinthera.2010.09.013_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","article-title":"Biochemical profile of risperidone, a new antipsychotic","volume":"247","author":"Leysen","year":"1988","journal-title":"J Pharmacol Exp Ther."},{"key":"10.1016\/j.clinthera.2010.09.013_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat","volume":"114","author":"van Beijsterveldt","year":"1994","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.09.013_bib13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/ddr.430330403","article-title":"In vivo pharmacological profile of 9-hydroxyrisperidone, the major metabolite of the novel antipsychotic risperidone","volume":"33","author":"Megens","year":"1994","journal-title":"Drug Dev Res."},{"key":"10.1016\/j.clinthera.2010.09.013_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s002130050726","article-title":"Distribution after repeated oral ad- ministration of different dose levels of risperidone and 9-hydroxy- risperidone in the brain and other tissues of rat","volume":"139","author":"Aravagiri","year":"1998","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.clinthera.2010.09.013_bib15","first-page":"307","article-title":"Bioequivalence study of a generic risperidone (Iperdal) in healthy Thai male volunteers","volume":"30","author":"Mahatthanatrakul","year":"2008","journal-title":"Songklanakarin J Sci Technol."},{"key":"10.1016\/j.clinthera.2010.09.013_bib16","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J Psychopharmacol."},{"key":"10.1016\/j.clinthera.2010.09.013_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2165\/00002018-200629070-00004","article-title":"Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?","volume":"29","author":"Aichhorn","year":"2006","journal-title":"Drug Saf."},{"year":"2004","series-title":"ASEAN guidelines for the conduct of bioavailability and bioequivalence studies","key":"10.1016\/j.clinthera.2010.09.013_bib18"},{"year":"2005","series-title":"Thailand Guidelines for the conduct of bioavailability and bioequivalence studies","key":"10.1016\/j.clinthera.2010.09.013_bib19"},{"year":"2000","series-title":"Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assem- bly, Edinburgh, Scotland","key":"10.1016\/j.clinthera.2010.09.013_bib20"},{"year":"2002","series-title":"Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations","key":"10.1016\/j.clinthera.2010.09.013_bib22"},{"year":"2001","series-title":"Bioanalytical method validation","key":"10.1016\/j.clinthera.2010.09.013_bib23"},{"key":"10.1016\/j.clinthera.2010.09.013_bib24","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0149-2918(03)80163-7","article-title":"Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers","volume":"25","author":"van Schaick","year":"2003","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.09.013_bib25","series-title":"Pharmaceutical Statistics: Practical and Clinical Applications","first-page":"210","author":"Bolton","year":"1997"},{"key":"10.1016\/j.clinthera.2010.09.013_bib26","series-title":"Pharmacokinetics: Regulatory, Industrial, Academic Perspectives","first-page":"479","article-title":"Statistical consideration for bioavailability\/bioequivalence studies","author":"Yuh","year":"1995"},{"year":"2001","series-title":"Guidance for Industry. Statistical approaches to establishing bioequivalence","key":"10.1016\/j.clinthera.2010.09.013_bib27"},{"key":"10.1016\/j.clinthera.2010.09.013_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF01143188","article-title":"Sample size determination for the two one-sided tests procedure in bioequivalence","volume":"20","author":"Liu","year":"1992","journal-title":"J Pharmacokinet Biopharm."},{"key":"10.1016\/j.clinthera.2010.09.013_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1023\/A:1011503032353","article-title":"On sample size calculation in bioequivalence trials [published correction appears in J Pharmacokinet Pharmacodyn. 2002; 29:101]","volume":"28","author":"Chow","year":"2001","journal-title":"J Pharmcokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2010.09.013_bib30","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1208\/aapsj0902013","article-title":"Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standard, quality controls and study samples","volume":"9","author":"Nowatzke","year":"2007","journal-title":"AAPS J."},{"key":"10.1016\/j.clinthera.2010.09.013_bib31","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.clinthera.2007.02.014","article-title":"Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: A summary of ten phase I clinical trials assessing taste, tablet disintegrating time, bioequivalence, and tolerability","volume":"29","author":"Thyssen","year":"2007","journal-title":"Clin Ther."},{"key":"10.1016\/j.clinthera.2010.09.013_bib32","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.talanta.2006.10.049","article-title":"Turbulent flow and ternary column-switching on-line clean-up system for high-throughput quantification of risperidone and its main metabolite by LC-MS\/MS application to a bioequivalence study","volume":"72","author":"Kousoulos","year":"2007","journal-title":"Talanta."},{"key":"10.1016\/j.clinthera.2010.09.013_bib33","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CPP47124","article-title":"Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers","volume":"47","author":"C\u00e1novas","year":"2009","journal-title":"Int J Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.09.013_bib34","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/jps.2600821125","article-title":"Bio-International 92, conference on bioavailability, bioequivalence, and pharmacokinetic studies","volume":"82","author":"Blume","year":"1993","journal-title":"J Pharm Sci."},{"key":"10.1016\/j.clinthera.2010.09.013_bib35","first-page":"193","article-title":"Pharmacokinetics of risperidone in chronic schizophrenic patients","volume":"30","author":"Borison","year":"1994","journal-title":"Psychopharmacol Bull."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000322X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929181000322X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:11:24Z","timestamp":1740805884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929181000322X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S014929181000322X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.09.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}